glp 1 gip dual agonist weight loss GIPR/GLP-1R therapies for diabetes and loss—chemistry, physiology, and clinical applications GIPR/GLP-1R dual agonist therapies for
Description
10.1517/17425255.2012.686603 166 ScheenA
2.2.3 Multifaceted Integration Integrating molecular biology, animal experiments, and clinical trials has increasingly become a hot topic in recent research, aiding in clarifying the mechanisms of action
Am J Manag Care (2011) 17(2 Suppl):s5970
Rapid weight loss, however, can also cause bone density loss
Evidence from both preclinical and clinical studies supports their antiinflammatory roles in the cardiovascular system, liver, kidneys, and joints
The most common side effects are gastrointestinal, including nausea and vomiting, which often improve over time
